Caffeine and taurine, which possess neuro-modulatory activity happen to be consumed together as part of the constituents of energy drinks, could have beneficial effects and prevent neuronal deterioration in Parkinson’s disease (PD).
Objective:
This study aimed to investigate behavioral and neurochemical effects of these two agents in an animal model of PD at two time points to evaluate possible neuro-protective or neuro-modulatory effects.
Methods:
Stereotaxic injection of 6-hydroxydopamine (6-OHDA) in rat striatum was used to model PD-like behavior in animals. Motor behavior was assessed by a characteristic rotation behavior response to the apomorphine challenge and dopamine levels in the striatum were quantified using HPLC-ED.
Results:
A reduction in apomorphine induced rotations following administration of caffeine and/or taurine as compared to the untreated lesioned group (controls) was shown. Significant decreases in dopamine levels were also seen in the ipsilateral side of 6-OHDA group, this effect was not significantly reversed in caffeine and taurine treated groups. Treatments partially restored the content of DA levels in the lesioned striatum.
Conclusions:
Current results demonstrated beneficial effects for the combination of caffeine and taurine in PD animal model, suggesting that consumption of both agents could be a new added therapeutic target for Parkinson’s disease prevention and treatment.
Abuirmeileh,A., Harkavyi,A., Lever,R., Biggs,C. S., & Whitton,P. S. (2007). Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson’s disease. Journal of neuroinflammation, 4, 19–19. doi: 10.1186/1742-2094-4-19
2.
Aguiar,L. M., Nobre,H. V.Jr, Macedo,D. S., Oliveira,A. A., Freitas,R. M., Vasconcelos,S. M.,... Viana,G. S. (2006). Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacology Biochemistry & Behavior, 84(3), 415–419. doi: 10.1016/j.pbb.2006.05.027
3.
Baskin,S. I., Hinkamp,D. L., Marquis,W. J., & Tilson,H. A. (1974). Effects of taurine on psychomotor activity in the rat. Neuropharmacology, 13(7), 591–594. doi: 10.1016/0028-3908(74)90047-1
4.
Biggs,C. S., Pearce,B. R., Fowler,L. J., & Whitton,P. S. (1992). Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. Journal of Neurochemstry, 59(5), 1702–1708. doi: 10.1111/j.1471-4159.1992.tb11001.x.
5.
Charvin,D., Medori,R., Hauser,R. A., & Rascol,O. (2018). Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nature Reviews Drug Discovery, 17(11), 804–822. doi: 10.1038/nrd.2018.136
6.
Che,Y., Hou,L., Sun,F., Zhang,C., Liu,X., Piao,F.,... Wang,Q. (2018). Taurine protects dopaminergic neurons in a mouse Parkinson’s disease model through inhibition of microglial M polarization. Cell Death & Disease, 9(4), 435–10.1038/s41419-018-0468-2
7.
Curran,C. P., & Marczinski,C. A. (2017). Taurine, caffeine, and energy drinks: Reviewing the risks to the adolescent brain. Birth Defects Research, 109(20), 1640–1648. doi: 10.1002/bdr2.1177
8.
de Araujo,D. P., De Sousa,C. N., Araujo,P. V., Menezes,C. E., Sousa Rodrigues,F. T., Escudeiro,S. S.,... Vasconcelos,S. M. (2013). Behavioral and neurochemical effects of alpha-lipoic Acid in the model of Parkinson’s disease induced by unilateral stereotaxic injection of -ohda in rat. Evidence-Based Complementary and Alternative Medicine, 2013, 571378–10.1155/2013/571378.
9.
Elkon,H., Melamed,E., & Offen,D. (2004). Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells. Journal of Molecular Neuroscience, 24(3), 387–400. doi: 10.1385/JMN:24:3:387
10.
Fahn,S., & Sulzer,D. (2004). Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx, 1(1), 139–154. doi: 10.1602/neurorx.1.1.139
11.
Faull,R. L., & Laverty,R. (1969). Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Experimental Neurology, 23(3), 332–340. doi: 10.1016/0014-4886(69)90081-8
12.
Giles,G. E., Mahoney,C. R., Brunye,T. T., Gardony,A. L., Taylor,H. A., & Kanarek,R. B. (2012). Differential cognitive effects of energy drink ingredients: caffeine, taurine, and glucose. Pharmacology Biochemistry & Behavior, 102(4), 569–577. doi: 10.1016/j.pbb.2012.07.004
13.
Hudson,J. L., van Horne,C. G., Strömberg,I., Brock,S., Clayton,J., Masserano,J.,... Gerhardt,G. A. (1993). Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Research, 626(1-2), 167–174. doi: 10.1016/0006-8993(93)90576-9
14.
Jellinger,K. A. (2010). Basic mechanisms of neurodegeneration: a critical update. Journal of cellular and molecular medicine, 14(3), 457–487. doi: 10.1111/j.1582-4934.2010.01010.x.
15.
Murakami,K., Miyake,Y., Sasaki,S., Tanaka,K., Fukushima,W., Kiyohara,C.,... Fukuoka Kinki Parkinson’s Disease Study, G. (2010). Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson’s disease: a case-control study in Japan. British Journal of Nutrition, 104(5), 757–764. doi: 10.1017/S0007114510001005
16.
Muralidhara,M., Yenisetti,S., & Yenisetti,S. (2017). Current Understanding on the Beneficial Role of Nutrition in Parkinson’s Disease –An Overview. Journal of Aging Science, 05–10.4172/2329-8847.1000177
17.
Negida,A., Elfil,M., Attia,Farahat, E., Gabr,M., Essam,A.,... Ahmed,H. (2017). Caffeine; the Forgotten Potential for Parkinson’s Disease. CNS & Neurological Disorders - Drug Targets, 16(6), 652–657. doi: 10.2174/1871527315666161107091149
18.
Nowak,D., & Jasionowski,A. (2015). Analysis of the Consumption of Caffeinated Energy Drinks among Polish Adolescents. International Journal of Environmental Research and Public Health, 12(7), 7910–7921. doi: 10.3390/ijerph120707910
19.
O’Neill,M. J., Murray,T. K., Whalley,K., Ward,M. A., Hicks,C. A., Woodhouse,S.,... Skolnick,P. (2004). Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson’s disease. European Journal of Pharmacology, 486(2), 163–174. doi: 10.1016/j.ejphar.2003.12.023
20.
Paxinos,G., & Watson,C. (2007). The rat brain in stereotaxic coordinates. Elsevier. doi:10.1016/j.psychres.2014.11.056
21.
Pinter,M. M., Alesch,F., Murg,M., Seiwald,M., Helscher,R. J., & Binder,H. (1999). Deep brain stimulation of the subthalamic nucleus for control of extrapyramidal features in advanced idiopathic parkinson’s disease: one year follow-up. Journal of Neural Transmission (Vienna), 106(7-8), 693–709. doi: 10.1007/s007020050190.
22.
Prasad,E. M., & Hung,S.-Y. (2020). Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease. Antioxidants (Basel, Switzerland), 9(10), 1007–10.3390/antiox9101007.
23.
Ross,G. W., Abbott,R. D., Petrovitch,H., Morens,D. M., Grandinetti,A., Tung,K. H.,... White,L. R. (2000). Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA, 283(20), 2674–2679. doi: 10.1001/jama.283.20.2674
24.
Shen,L. (2015). Associations between B Vitamins and Parkinson’s Disease. Nutrients, 7(9), 7197–7208. doi: 10.3390/nu7095333
25.
Tang,X. W., Deupree,D. L., Sun,Y., & Wu,J. Y. (1996). Biphasic effect of taurine on excitatory amino acid-induced neurotoxicity. Advances in Experimental Medicine and Biology, 403, 499–505. doi: 10.1007/978-1-4899-0182-8_54
26.
Tieu,K. (2011). A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harbor perspectives in medicine, 1(1), a009316–a009316. doi: 10.1101/cshperspect.a009316
27.
Wang,F., Xiao,C., & Ye,J. H. (2005). Taurine activates excitatory non-synaptic glycine receptors on dopamine neurones in ventral tegmental area of young rats. Journal of Physiology, 565(Pt 2), 503–516. doi: 10.1113/jphysiol.2005.085423
28.
Xu,K., Xu,Y. H., Chen,J. F., & Schwarzschild,M. A. (2002). Caffeine’s neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neuroscience Letters, 322(1), 13–16. doi: 10.1016/s0304-3940(02)00069-1
29.
Yu,L., Shen,H. Y., Coelho,J. E., Araújo,I. M., Huang,Q. Y., Day,Y. J.,... Chen, J. F. (2008). Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Annals of Neurology, 63(3), 338–346. doi: 10.1002/ana.21313
